Herbal and nutritional supplement direct seller has reached 85% solar power use at its US facilities while also reducing landfill waste from those sites more than 90%, cutting its US shipping routes by half and consolidating four distribution centers in Europe into one operating on wind power.

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

The drug maker has its eye on six Phase III or Phase III-ready programs that it hopes will return the company to growth. It also highlighted investments in AI and digital technology.

The FDA would only withdraw a rare disease gene therapy for “pretty clear” reasons, such as when there is minimal benefit with extensive side effects. The one-and-done nature of administration also makes withdrawal easier, CBER Director Peter Marks says.